id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
cord-324908-ptlpsnfo	Cao, Huiling	Convalescent plasma: possible therapy for novel coronavirus disease 2019	2020-05-02		.txt	text/plain	2799	130	47	In 1995, a small study reported that eight patients received 150 to 400 mL of convalescent plasma and seven survived, for a case fatality rate of 12.5% in comparison to 80% in patients without convalescent plasma treatment. Convalescent plasma as a potential therapy for COVID-19 Use of convalescent plasma in Ebola virus infection Passive transfer of antibodies protects immunocompetent and immunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication Evaluation of convalescent plasma for Ebola virus disease in Guinea Use of convalescent plasma therapy in SARS patients in Hong Kong Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients A study in scarlet-convalescent plasma for severe influenza The use of hyperimmune serum for severe influenza infections Treatment with convalescent plasma for influenza A (H5N1) infection Characteristics and outcome of mechanically ventilated patients with 2009 H1N1 influenza in Bosnia and Herzegovina and Serbia: impact of newly established multidisciplinary intensive care units Severe H1N1-associated acute respiratory failure in immunocompromised children Anti-Ebola virus antibody levels in convalescent plasma and viral load after plasma infusion in patients with Ebola virus disease The use of Lassa fever convalescent plasma in Nigeria Convalescent whole blood, plasma and serum in the prophylaxis of measles Ribavirin, human convalescent plasma and anti-beta3 integrin antibody inhibit infection by Sin Nombre virus in the deer mouse model Treatment of MERS-CoV: information for clinicians Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks.	cache/cord-324908-ptlpsnfo.txt	txt/cord-324908-ptlpsnfo.txt
